References
1 Zhou F, Yu T, Du R et al.Clinical course and risk factors for
mortality of adult inpatients with COVID-19 in Wuhan, China: a
retrospective cohort study. Lancet 2020; 395: 1054-1062.
2. Parastoo T, Samane E, Milad Ci et al. A review of potential suggested
drugs for coronavirus disease (COVID-19) treatment. Eur J Pharmacol
2021;173890.
3. Alexandre BC, Fernando GZ, Regis GR et al. Hydroxychloroquine with or
without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med
2020;383(21):2041-2052.
4. David AB, Roy MG and Fernando JM. Severe Covid-19. N Engl J Med 2020;
383:2451-2460.